Intensity

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Retrieved on: 
Freitag, Mai 10, 2024
Patient, SOC, CTCAE, Magnetic resonance imaging, Tumor microenvironment, FDA, MRI, Therapy, Lymph, Necrosis, Neoplasm, PCR, Research, Cancer, Intensity, Mortality, NCI, TNBC, Standard of care, Aggression, European, National Cancer Institute, Pharmaceutical industry

The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.

Key Points: 
  • The INVINCIBLE-4 Study is an open-label randomized two-cohort phase 2 clinical trial.
  • SAKK shall undertake the trial as the "Legal Sponsor" of the study, with the regulatory agencies in Switzerland and the European Union as described in the study protocol.
  • SAKK will also ensure that all investigators and personnel who participate in the study are informed and trained.
  • Intensity shall fund the study, provide the investigational drug product, and other necessary information to conduct the trial.

Survey on credit terms and conditions in euro-denominated securities financing and OTC derivatives markets (SESFOD) - March 2024

Retrieved on: 
Donnerstag, April 18, 2024
Reproduction, European Central Bank, Bank for International Settlements, Commodity, Attention, Documentation, ECB, Liquidity, Insurance, Risk, Committee, Frankfurt, Bank, Internal, Table, Equity, Credit, OTC, Foreign, Interest, Intensity, ISDA, Government, Total, Eurosystem, Convertible, Palladium

Survey on credit terms and

Key Points: 
    • Survey on credit terms and
      conditions in euro-denominated
      securities financing and OTC
      derivatives markets (SESFOD)
      March 2024
      The Eurosystem conducts a three-monthly qualitative survey on credit terms and
      conditions in euro-denominated securities financing and over-the-counter (OTC)
      derivatives markets.
    • The survey questions are grouped into three sections:
      1.

      counterparty types ? credit terms and conditions for various counterparty
      types in both securities financing and OTC derivatives markets;

      2.

      securities financing ? financing conditions for various collateral types;

      3.

      non-centrally cleared OTC derivatives ? credit terms and conditions for
      various derivative types.

    • The survey focuses on euro-denominated instruments in securities financing and
      OTC derivatives markets.
    • For securities financing, the survey refers to the
      euro-denominated securities against which financing is provided, rather than the
      currency of the loan.
    • Reporting institutions should report on their global credit terms, so the survey is
      aimed at senior credit officers responsible for maintaining an overview of the
      management of credit risks.
    • SESFOD March 2024

      2

      March 2024 SESFOD results
      (Review period from December 2023 to February 2024)
      The March 2024 Survey on credit terms and conditions in euro-denominated
      securities financing and OTC derivatives markets (SESFOD) reports qualitative
      changes in credit terms between December 2023 and February 2024.

    • Looking at credit terms and conditions for the various types of non-centrally cleared
      OTC derivative, initial margin requirements increased slightly for all derivative types.
    • Survey respondents reported mostly unchanged conditions as regards the maximum
      amount of exposure and the maximum maturity of trades.
    • Moreover, they reported that the volume of valuation disputes had
      declined for all derivative types except credit derivatives.
    • The survey asked respondents to compare credit terms
      and conditions on the cut-off date for the March 2024 survey round (i.e.
    • Compared with the
      previous year, overall terms and conditions for securities financing and OTC
      derivatives transactions had eased somewhat across all counterparties, while credit
      standards for funding secured against various types of collateral and non-price terms
      in OTC derivatives markets were generally tighter.
    • Credit terms and conditions for various counterparty types in both
      securities financing and OTC derivatives markets
      Overall credit terms and conditions eased between December 2023 and
      February 2024 (Chart A).
    • The overall easing of conditions masked some
      heterogeneity between price and non-price terms, and across different types of
      counterparty, though reported changes were relatively small.
    • Credit terms and conditions for various types of non-centrally
      cleared OTC derivative
      Initial margin requirements increased slightly for all derivative types.
    • Meanwhile, they reported
      unchanged conditions for credit derivatives referencing sovereigns and commodities,
      as well as a slight deterioration for credit derivatives referencing corporates and
      structured credit products.
    • The survey asked respondents to compare the credit terms and conditions observed
      on the cut-off date for the March 2024 survey (i.e.
    • Compared with the previous year, overall terms and conditions for securities
      financing and OTC derivatives transactions had eased somewhat across all
      counterparties.
    • Survey respondents reported that non-price credit terms in OTC derivatives
      markets had tightened somewhat for almost all types of derivative relative to
      the previous year.

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Retrieved on: 
Dienstag, März 26, 2024
Immunotherapy, Society, Therapy, ASCO, SITC, PRTG, Intensity, Annual general meeting, Pharmaceutical industry

WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS).

Key Points: 
  • WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported that it has completed selling its equity holding in Intensity Therapeutics (NASDAQ: INTS).
  • Portage was an early INTS investor and during the past few months, Portage has been able to monetize its equity holdings in INTS and bring in proceeds, net of related expenses, totaling $2.8M of non-dilutive funding.
  • The Company will use the proceeds to further fund its PORT-6 Phase 1a portion of the ADPORT-601 trial.
  • “We are excited with the potential of the Company’s adenosine platform and are focusing our efforts on advancing its ADPORT-201 Phase 1a/1b clinical trial of PORT-6 (adenosine 2A inhibitor) and PORT-7 (adenosine 2B inhibitor) in selected solid tumors.”

Survey on credit terms and conditions in euro-dominated securities financing and OTC derivatives markets (SESFOD) - December 2023

Retrieved on: 
Samstag, Februar 3, 2024
Intensity, Insurance, Commodity, Eurosystem, Committee, Element, ISDA, Total, Attention, Var, Frankfurt, Table, Foreign, Documentation, OTC, Risk, Internal, Bank for International Settlements, Credit, European Central Bank, Government, Overalls, Bank, Liquidity, ECB, Interest, Convertible, Reproduction, Palladium
Key Points: 

<ul></ul>

Leading Utilities Increase Business Customer Engagement by Offering Reliable Energy Partnerships

Retrieved on: 
Dienstag, Dezember 19, 2023
Cogent, Intensity, Haggerty, Business, Research, Customer, Behavior, Energy, Communication, Index, ECR, Retail

Despite the trending decline, 17 outstanding utilities, recognized today as Escalent’s 2023 Business Customer Champions, have scored well above their industry peers for building engaged customer relationships.

Key Points: 
  • Despite the trending decline, 17 outstanding utilities, recognized today as Escalent’s 2023 Business Customer Champions, have scored well above their industry peers for building engaged customer relationships.
  • Business Customer Champions are offering a valuable array of opt-in programs with low-effort enrollment processes, leading to 6% higher Product Benefits Awareness Index scores.
  • “In tough economic times, affordability, transparency and community connections are key to business customer engagement,” Haggerty continued.
  • “Utilities that prove their value as a vital part of the local economic community and act as a trusted energy advisor for their business customers will pave the way to better relationships.”
    Escalent is pleased to name these 17 utilities as our 2023 Business Customer Champions.

Kansas City Proton Institute Begins Cancer Treatments with Advanced MEVION S250i Proton Therapy System

Retrieved on: 
Freitag, Dezember 22, 2023
Oncology, Medical Devices, Health, Hospitals, Surgery, Radiology, Proton, Liver, Intensity, Proton therapy, Risk, Multimedia, Stomach, Physician, Lung, Breast, Spinal cord, KCPI, Brain, Doctor of Philosophy, MLC, Motion, Head, 3D, Neoplasm, Prostate, Esophagus, Patient, Radiation, Neck, Skin, Medical imaging

Kansas City Proton Institute (KCPI), the first physician-led proton therapy center in the Midwest, and Mevion Medical Systems announced today that the first four patients were treated at Kansas City Proton Institute on Dec. 19, with the MEVION S250i Proton Therapy System® .

Key Points: 
  • Kansas City Proton Institute (KCPI), the first physician-led proton therapy center in the Midwest, and Mevion Medical Systems announced today that the first four patients were treated at Kansas City Proton Institute on Dec. 19, with the MEVION S250i Proton Therapy System® .
  • (Photo: Business Wire)
    Kansas City Proton Institute recently opened the doors to its new facility that houses the region’s first Mevion compact proton therapy system.
  • The MEVION S250i system at KCPI also integrates an advanced 3D imaging system and will install the C-RAD Catalyst PT surface-guided tracking system, enabling a cutting-edge Image-Guided Proton Therapy configuration for high-precision patient positioning and intra-fraction motion management.
  • “We congratulate Kansas City Proton Institute for starting treatment with the Mevion proton therapy system,” said Tina Yu, PhD, chief executive officer and president of Mevion Medical Systems.

Siteman Cancer Center Begins Treatment with Latest Mevion Proton Therapy System

Retrieved on: 
Donnerstag, November 16, 2023
Research, Hospitals, Health Technology, Radiology, Health, University, Science, Education, Oncology, Proton, Lung, Neck, NCI-designated Cancer Center, Brain, Radiation, Proton therapy, Head, Barnes-Jewish Hospital, Risk, FLASH, Intensity, Hospital, Scan (company), Varian Medical Systems, Breast cancer, NCI, Patient, Multimedia, Heart, IGRT, Image-guided radiation therapy, Metal toxicity, MLC, 3D, Professor, Medical imaging, Pharmaceutical industry

Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.

Key Points: 
  • Mevion Medical Systems announced today that the world’s first single-room proton therapy system has completed the upgrade to the latest MEVION S250i Proton Therapy System® with FLASH* capabilities, and has begun treating patients in November at the S. Lee Kling Proton Therapy Center at Siteman Cancer Center, Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO.
  • View the full release here: https://www.businesswire.com/news/home/20231116635095/en/
    The MEVION S250i Proton Therapy System (Photo: Business Wire)
    Siteman Cancer Center is an NCI-designated Comprehensive Cancer Center that draws patients from Missouri, Southern Illinois and beyond.
  • “Our team also looks forward to advancing FLASH dosimetry research.”
    This latest system incorporates Mevion's cutting-edge HYPERSCAN® Pencil Beam Scanning for Intensity Modulated Proton Therapy (IMPT) with a proton MLC, along with an advanced 3D imaging system for high-precision Image-Guided Radiation Therapy (IGRT) and adaptive therapy.
  • These latest capabilities are the result of a collaborative effort between Mevion and Siteman Cancer Center, initiated in 2019.

Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer

Retrieved on: 
Dienstag, Dezember 12, 2023
Senior, Therapy, Joseph Talamo, CFO, Intensity, Biotechnology, Patient, Caladrius Biosciences, Market for corporate control, Controller, Cancer, CPA, BBA, Hofstra University, OSI Pharmaceuticals, Pharmaceutical industry

SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than 25 years of leadership experience in the biotechnology space, Mr. Talamo most recently served as Senior Vice President and Chief Financial Officer of HiberCell. Mr. John Wesolowski will remain as the Company's Principal Accounting Officer and Controller. 

Key Points: 
  • An accomplished executive with more than 25 years of leadership experience in the biotechnology space, Mr. Talamo most recently served as Senior Vice President and Chief Financial Officer of HiberCell.
  • Mr. John Wesolowski will remain as the Company's Principal Accounting Officer and Controller.
  • "I am delighted to welcome Joe to Intensity, his wealth of experience as a biotechnology executive and track record of success in leading financial operations will prove invaluable as we transition to a late-stage clinical company," said Lewis H. Bender , President and Chief Executive Officer of Intensity.
  • As CFO, Mr. Talamo will develop and implement Intensity's financial strategies and lead financial reporting, finance corporate development, strategy and investor relations efforts while supporting the Company's overall business goals.

Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS

Retrieved on: 
Freitag, Dezember 8, 2023
Woman, Safety, Therapy, Ottawa Hospital Research Institute, Intensity, Podium, Breast cancer, Fatigue, Patient, Gene expression profiling, Necrosis, The Ottawa Hospital, T helper cell, Immunotherapy, Breast, CD4, Gene expression, Biomarker, Mastectomy, MD, Nausea, Diagnosis, Cancer, University, Downregulation and upregulation, Neoplasm, News, Publication, Injection, NK, Vaccine, Medical imaging

"A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.

Key Points: 
  • "A large unmet need in the treatment of breast cancer is that the majority of breast cancers are immune quiescent; resulting in minimal response to immunotherapies.
  • A functional pathway enrichment analysis was conducted and confirmed positive changes in T-cell activation, lymphocyte activation and inflammatory response.
  • Over 95% of treatment-emergent adverse events (TEAEs) were low grade 1 or 2 primarily localized pain, fatigue, and nausea.
  • We see the potential opportunity for our technology and drug products in both the metastatic and presurgical settings for many types of cancers."

Nearly Half of Unpaid Caregivers Fear the Holidays Could Harm Their Mental Health, According to New ARCHANGELS Survey

Retrieved on: 
Donnerstag, November 30, 2023
Holiday, Omnichannel, Research, Organization, Entrepreneurship, National Movement, Intensity, Magic, Health, Caregiver, Nation, Mental health, Residential care, Tourism

BOSTON, Nov. 30, 2023 /PRNewswire/ -- ARCHANGELS, a women-owned, omni-channel platform supporting the 43% of adults serving as unpaid caregivers in the US, surveyed caregivers across the nation to understand the impact the holiday season is having on all aspects of their health. The results confirm the massive opportunity that exists to ramp up support for this essential population during what is dubbed the "most wonderful time" of the year but often feels just the opposite. In fact, 40% of caregivers are extremely concerned the holidays could actually harm their mental health, and 1 in 4 would rather just skip the holidays all together.

Key Points: 
  • In fact, 40% of caregivers are extremely concerned the holidays could actually harm their mental health, and 1 in 4 would rather just skip the holidays all together.
  • The 2023 ARCHANGELS Caregivers & Holidays Survey was designed to build upon the existing ARCHANGELS research and reinforces how out of sync the holiday hype can be with caregiver intensity.
  • 3 out of 4 'in the red' caregivers worry their mental health will take a hit during the holidays.
  • Holiday Escape: A quarter of unpaid caregivers would prefer to just skip the holidays all together this year.